Release Date: Nov 2018
CC: PC, MK, PBL, ICS, PR, SBP
Darshana Jhala, MD, B Mus
Chief of Pathology and Laboratory Medicine Services, CMC VAMC, Philadelphia, PA; Professor, University of Pennsylvania School of Medicine, Philadelphia, PA
Description:
Endoscopy, along with ultrasound-guided fine needle aspiration (FNA), is now a standard of care in diagnosis and staging of various deep-seated tumors. Molecular testing on EUS- (Endoscopic Ultrasound) and EBUS- (Endobronchial Ultrasound) guided FNA is becoming increasingly common in developing precision therapeutics. New targetable mutations continue to guide therapy for deep-seated tumors. In recent times, demonstration of PD-L1 has shown great promise in treatment of lung carcinoma. Its utilization on EBUS-guided FNA samples including cell block continues to be explored. Recently, performing HER2 testing for adenocarcinoma of the upper gastrointestinal tract on small tissue samples, including on FNA samples,has been recommended. Similarly, determination of mutational status in GIST tumors has resulted in a selection of therapeutic options. EUS-guided FNA samples from the gastrointestinal tract are best suited for performing molecular testing on these cases. Finally, pancreatic adenocarcinoma, a highly lethal tumor, continues to pose diagnostic as well as treatment challenges. This webcast will demonstrate use of a simple algorithmic approach on EUS and EBUS FNA specimens which helps explore common lesions encountered in day-to-day practice in order to arrive at a diagnosis, leading to the appropriate utilization of molecular testing that could further drive management to improve survival.
After attending this session, participants will be able to:
- Identify common lesions encountered in EUS and EBUS FNA that require personalized diagnosis and therapeutics.
- Recognize the value of EUS-guided FNA samples in directing therapy for pancreatic adenocarcinoma.
- Utilize EUS FNA-guided samples in performing molecular testing for gastroesophageal adenocarcinoma and GIST tumors.
- Recognize the importance of using EBUS-FNA in ancillary testing of PD-L1 in lung adenocarcinoma.
Who should attend? Practicing Pathologists, Residents, Doctoral Scientists, Pathologists’ Assistants, Laboratory Managers, Cytotechnologists, Histotechnologists, Stude